Cell-based gene therapy for neurodegenerative diseases
AssigneeALSaTECH, Inc.
InventorsClaude NICOLAU, Claudine KIEDA, Reynald THINARD, Ruth GREFERATH, Melanie CHEVALIER
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to cell-based gene therapies, including those targeting, by way of non-limiting example, TDP43 and Aβ aggregates, for the use in neurodegenerative disorders, including without limitation Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease, respectively.
Claims99
A method for treating or preventing a neurodegenerative disease, comprising administering to a subject a cell, the cell being a microvascular endothelial cell, or precursor thereof, engineered to release a therapeutic protein or peptide at a site of therapeutic action.
The method of any one of the above claims, wherein the microvascular endothelial cell or a precursor thereof is an autologous microvascular endothelial cell or a precursor thereof that is derived from the patient to whom it is administered.
The method of any one of the above claims, wherein the autologous microvascular endothelial cell or a precursor thereof is transfected with a nucleic acid vector encoding the therapeutic antibody or antibody fragment.
The method of any one of the above claims, wherein the administering is by injection or infusion.
The method of any one of the above claims, wherein the autologous transfected cells are delivered to and/or past the blood brain barrier (BBB) and/or delivered into the brain.
The method of any one of the above claims, wherein the method provides for organ-specific or early progenitors of endothelial cells to carry therapeutic antibody or antibody fragment into the brain.
The method of any one of the above claims, wherein the method allows for homing properties of an autologous microvascular endothelial cell or a precursor thereof to transfer molecules in an organospecific manner.
The method of any one of the above claims, wherein the therapeutic antibody or antibody fragment is directed against a protein selected from TDP43, beta-amyloid (Aβ), SOD-1, FUS/TLS, α-synuclein, Tau protein, and IAPP.
The method of any one of the above claims, wherein the site of therapeutic action is a neuron.
The method of any one of the above claims, wherein the site of therapeutic action is the CNS.
The method of any one of the above claims, wherein the site of therapeutic action is the brain.
The method of any one of the above claims, wherein the site of therapeutic action is the liver.
The method of any one of the above claims, wherein the site of therapeutic action is the pancreas or the heart.
The method of any one of the above claims, wherein the cell is selected from HucPEC 55.1 (CNCM Nos. 1-4220), HucPEC 55.2 (CNCM Nos. 1-4221), HEPC.CB1, and HEPC.CB2.
The method of any one of the above claims, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO:
- 13.
The method of any one of the above claims, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO:
- 14.
The method of any one of the above claims, wherein the therapeutic protein or peptide, or antibody or antibody fragment, comprises a CDR having an amino acid sequence selected from one or more of SEQ ID NOs:
- 19-24, optionally, wherein CDR1 is selected from SEQ ID NO:
- 19 or 22, wherein CDR2 is selected from SEQ ID NO:
- 20 or 23, wherein CDR3 is selected from SEQ ID NO:
- 21 or 24.
The method of any one of the above claims, wherein the therapeutic protein or peptide, or antibody or antibody fragment further comprises a signal peptide of SEQ ID NO:
- 17 or SEQ ID NO:
- 18.
The method of any one of the above claims, wherein the cell comprises a nucleic acid sequence having at least 95% identity to one of SEQ ID NOs:
- 1-6 or a codon optimized form thereof, optionally selected from SEQ ID NO:
- 1 and SEQ ID NO:
- 4.
The method of any one of the above claims, wherein the cell comprises a nucleic acid vector comprising a nucleic acid sequence of one or more of SEQ ID NOs:
- 83-88, or a codon optimized form thereof.
A method for making a cell-based therapy for the treatment of a neurodegenerative disorder in a subject in need thereof, the method comprising:
- a. obtaining a sample of cells from the subject having the neurodegenerative disorder, the sample comprising microvascular endothelial cells;
- b. isolating the microvascular endothelial cells;
- c. transfecting ex vivo the microvascular endothelial cells with a nucleic acid vector encoding a therapeutic protein or peptide, or antibody or antibody fragment;
- and
- d. formulating the transfected cells for reintroduction into the subject.
An engineered cell, or precursor thereof, comprising a nucleic acid vector encoding a protein or peptide, or therapeutic antibody or antibody fragment.
A therapeutic TDP43-targeting antibody comprising a peptide having an amino acid sequence at least 95% identical to SEQ ID NO:
- 13.
A therapeutic TDP43-targeting antibody comprising one or more CDRs having an amino acid sequence selected from SEQ ID NOs:
- 19-24 or a variant having one or more substitutions.
A therapeutic TDP43-targeting antibody comprising one or more CDRs having an amino acid sequence selected from SEQ ID NOs:
- 19-24.
A therapeutic 3 amyloid-targeting antibody comprising a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO:
- 94.
A therapeutic 3 amyloid-targeting antibody comprising one or more CDRs having an amino acid sequence selected from SEQ ID NOs:
- 36-41 or a variant having one or more substitutions.
A therapeutic 3 amyloid-targeting antibody comprising one or more CDRs having an amino acid sequence selected from SEQ ID Nos:
- 36-41.
Dependencies are inferred from the claim text.